Trevi Therapeutics (TRVI) Cash from Operations (2018 - 2026)

Trevi Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 16689000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 23.83% year-over-year to 16689000.0 in Q1 2026; TTM through Mar 2026 was 45301000.0, a 9.78% decrease from a year earlier, with the FY2025 full-year figure at 42089000.0, down 10.02% from the prior year.
• Cash from Operations declined to 16689000.0 in Q1 2026 per TRVI's latest filing, from 7631000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 6176000.0 in Q2 2022 and bottomed at 16689000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 8683000.0 (2024), against an average of 9230529.41.
• Across the five-year window, Cash from Operations climbed 21.8% in 2022 and tumbled 59.89% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 6331000.0 in 2022, then dropped by 0.44% to 6359000.0 in 2023, then slumped by 50.18% to 9550000.0 in 2024, then rose by 20.09% to 7631000.0 in 2025, then sank by 118.7% to 16689000.0 in 2026.
• Per Business Quant, the three latest TRVI Cash from Operations figures stand at 16689000.0 (Q1 2026), 7631000.0 (Q4 2025), and 10880000.0 (Q3 2025).